Ruffo Mariarosa, Parisi Ortensia Ilaria, Patitucci Francesco, Dattilo Marco, Malivindi Rocco, Amone Fabio, Morelli Catia, Nigro Alessandra, Sisci Diego, Puoci Francesco
Department of Pharmacy, Health and Nutritional Sciences, University of Calabria, 87036 Rende, Italy.
Macrofarm s.r.l., c/o Department of Pharmacy, Health and Nutrition Sciences, University of Calabria, 87036 Rende, Italy.
J Funct Biomater. 2020 Jul 8;11(3):48. doi: 10.3390/jfb11030048.
The ionic gelation technique allows us to obtain nanoparticles able to function as carriers for hydrophobic anticancer drugs, such as 5-fluoruracil (5-FU). In this study, reticulated chitosan- docosahexaenoic acid (Chi-DHAr) nanoparticles were synthesized by using a chemical reaction between amine groups of chitosan (Chi) and carboxylic acids of docosahexaenoic acid (DHA) and the presence of a link between Chi and DHA was confirmed by FT-IR, while the size and morphology of the obtained Chi-DHAr nanoparticles was evaluated with dynamic light scattering (DLS) and scanning electron microscopy (SEM), respectively. Drug-loading content (DLC) and drug-loading efficiency (DLE) of 5-FU in Chi-DHAr nanoparticles were 33.74 ± 0.19% and 7.9 ± 0.26%, respectively, while in the non-functionalized nanoparticles (Chir + 5FU), DLC, and DLE were in the ranges of 23.73 ± 0.14%, 5.62%, and 0.23%, respectively. The in vitro release profile, performed in phosphate buffer saline (PBS, pH 7.4) at 37 °C, indicated that the synthetized Chi-DHAr nanoparticles provided a sustained release of 5-FU. Based on the obtained regression coefficient value (R), the first order kinetic model provided the best fit for both Chir and Chi-DHAr nanoparticles. Finally, cytotoxicity studies of chitosan, 5-FU, Chir, Chir + 5-FU, Chi-DHAr, and Chi-DHAr + 5-FU nanoparticles were conducted. Overall, Chi-DHAr nanoparticles proved to be much more biocompatible than Chir nanoparticles while retaining the ability to release the drug with high efficiency, especially towards specific types of cancerous cells.
离子凝胶技术使我们能够获得可作为疏水性抗癌药物载体的纳米颗粒,如5-氟尿嘧啶(5-FU)。在本研究中,通过壳聚糖(Chi)的胺基与二十二碳六烯酸(DHA)的羧酸之间的化学反应合成了网状壳聚糖-二十二碳六烯酸(Chi-DHAr)纳米颗粒,通过傅里叶变换红外光谱(FT-IR)确认了Chi和DHA之间连接的存在,而分别用动态光散射(DLS)和扫描电子显微镜(SEM)评估了所得Chi-DHAr纳米颗粒的尺寸和形态。5-FU在Chi-DHAr纳米颗粒中的载药量(DLC)和载药效率(DLE)分别为33.74±0.19%和7.9±0.26%,而在未功能化的纳米颗粒(Chir + 5FU)中,DLC和DLE分别在23.73±0.14%、5.62%和0.23%的范围内。在37°C的磷酸盐缓冲盐水(PBS,pH 7.4)中进行的体外释放曲线表明,合成的Chi-DHAr纳米颗粒提供了5-FU的缓释。基于获得的回归系数值(R),一级动力学模型对Chir和Chi-DHAr纳米颗粒均提供了最佳拟合。最后,对壳聚糖、5-FU、Chir、Chir + 5-FU、Chi-DHAr和Chi-DHAr + 5-FU纳米颗粒进行了细胞毒性研究。总体而言,Chi-DHAr纳米颗粒被证明比Chir纳米颗粒具有更高的生物相容性,同时保留了高效释放药物的能力,尤其是对特定类型的癌细胞。